Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis.
OBJECTIVE
To compare the cost effectiveness of rabeprazole (RAB) and ranitidine (RAN) in acute and maintenance therapy for erosive esophagitis using symptom response, rather than endoscopic healing, as the clinical outcome.


METHODS
Decision analysis was used to model the cost effectiveness of competing therapies based on the results of clinical trials of RAB versus RAN and estimates from the medical literature.


METHODS
The model's base case scenario compared brand-name RAB (estimated average wholesale price) with generic RAN (25% of the average wholesale price of brand-name RAN). Medical costs for hospitalizations, procedures, and office visits reflected 1998 Medicare payments. The 1-year maintenance model accounted for drug-class switching and symptomatic, rather than endoscopic, recurrences. Effectiveness was reported as the percentage of patients in whom a symptomatic recurrence was prevented. The cost per symptomatic recurrence prevented was reported as an average and an incremental cost-effectiveness ratio.


RESULTS
The per-patient cost of RAB therapy was higher than that of RAN therapy ($2020 vs $1917); RAB therapy, however, was more effective than RAN therapy in preventing symptomatic recurrences (74% vs 41%). The average cost-effectiveness ratio was lower for RAB therapy than for RAN therapy ($2748 per symptomatic recurrence prevented vs $4719 per symptomatic recurrence prevented). The cost of preventing one additional symptomatic recurrence with RAB rather than RAN was $313 (incremental cost-effectiveness ratio). Sensitivity analysis conducted on key clinical and cost variables supported the robustness of the decision model.


CONCLUSIONS
This analysis demonstrates that management of esophagitis with RAB is more effective, and may be more cost effective, than management with generic RAN, despite RAB's higher per-unit cost.
Ofman
J J
JJ
Cedars-Sinai Department of Medicine and Health Services Research, Division of Gastroenterology, Los Angeles, CA, USA.
Yamashita
B D
BD
Siddique
R M
RM
Larson
L R
LR
Willian
M K
MK
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles / Q000008:administration & dosage / Q000191:economics*; D003362:Cost-Benefit Analysis; D003663:Decision Trees; D016527:Drug Costs / Q000706:statistics & numerical data; D016568:Drugs, Generic; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000191:economics*; D004942:Esophagitis, Peptic / Q000188:drug therapy* / Q000209:etiology; D005764:Gastroesophageal Reflux / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D017048:Health Care Costs / Q000706:statistics & numerical data; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000191:economics*; D006801:Humans; D008329:Managed Care Programs / Q000191:economics; D009853:Omeprazole / Q000031:analogs & derivatives; D054328:Proton Pump Inhibitors; D064750:Rabeprazole; D011899:Ranitidine / Q000008:administration & dosage / Q000191:economics*; D014481:United States
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles; D016568:Drugs, Generic; D004791:Enzyme Inhibitors; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors; D064750:Rabeprazole; D011899:Ranitidine; D009853:Omeprazole